Novo Nordisk A/S (NVO)
NYSE · Healthcare · Drug Manufacturers - General
Novo Nordisk A/S is a Healthcare company with a market capitalization of $204.55B, a trailing P/E ratio of 11.4, and a dividend yield of 3.86%.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025 · in DKK
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q2 2026 | August 5, 2026 | $0.96 | $0.82 | +17.1% |
| Q1 2026 | May 6, 2026 | $6.63 | $6.96 | -4.7% |
| Q4 2025 | February 3, 2026 | $6.04 | $5.90 | +2.4% |
| Q3 2025 | November 5, 2025 | $1.02 | $0.77 | +32.5% |
| Q2 2025 | August 6, 2025 | $5.96 | $6.00 | -0.7% |
| Q1 2025 | May 7, 2025 | $6.53 | $6.07 | +7.6% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 31,094,150 | — | 3.3 | +11.9% |
| June 30, 2026 | 27,780,646 | — | 2.2 | +13.5% |
| June 15, 2026 | 24,478,152 | — | 1.7 | +7.9% |
| May 29, 2026 | 22,683,612 | — | 2.0 | +4.4% |
| May 15, 2026 | 21,723,616 | — | 1.2 | +55.2% |
| April 30, 2026 | 13,996,269 | — | 1.0 | -17.8% |
| April 15, 2026 | 17,019,927 | — | 1.1 | -14.6% |
| March 31, 2026 | 19,927,815 | — | 1.1 | -19.3% |
Other Drug Manufacturers - General Stocks
Frequently Asked Questions
What is Novo Nordisk A/S's market cap?
As of August 13, 2026, Novo Nordisk A/S (NVO) has a market capitalization of $204.55B.
What is Novo Nordisk A/S's P/E ratio?
Novo Nordisk A/S trades at a trailing price-to-earnings (P/E) ratio of 11.4. Its forward P/E is 13.5.
Does Novo Nordisk A/S pay a dividend?
Yes — Novo Nordisk A/S pays a dividend yielding 3.86%, an annual payout of $11.70 per share.
What sector is NVO in?
Novo Nordisk A/S is in the Healthcare sector, specifically the Drug Manufacturers - General industry.
What is Novo Nordisk A/S's short interest?
As of the July 15, 2026 FINRA settlement, 31,094,150 NVO shares were sold short. Days to cover: 3.3. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Novo Nordisk A/S's revenue?
In its latest reported fiscal year (ending December 31, 2025), Novo Nordisk A/S reported revenue of 309.06B DKK and net income of 102.43B DKK.
Ask your own questions about NVO
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.